Table 3.
Summary of disease control and resensitization/hypersensitization
| Number | Tumor type | Efficacy* | Subsequent treatment and therapeutic effect | Resensitization/ Hypersensitization |
OS (month) | Survive | ||
|---|---|---|---|---|---|---|---|---|
| Time after first administration (month) | Treatment | Efficacy* | ||||||
| T01001 | Ovarian serous adenocarcinoma | SD (+ 4.7%) | 7+ | Paclitaxel + Carboplatin | CR | Resensitization | 36+ | Yes |
| 7+ | Paclitaxel + Carboplatin + Bevacizumab | |||||||
| 12+ | Bevacizumab+Niraparib mesylate | |||||||
| T01003 | Papillary thyroid carcinoma | CR (-39.1%) | ≈ 13 | Lenvatinib | CR | Hypersensitization | 31+ | Yes |
| ≈ 17 | Surgical resection# | |||||||
| T01005 | Pancreatic adenocarcinoma | SD (+ 12.0%) | 2 |
Irinotecan liposome+Oxaliplatin +(5-Fluorouracil+Calcium folinate) |
PR | Hypersensitization | 28+ | Yes |
| 2+ |
Radiotherapy + Tegafur/ Gimeracil/Oteracil Potassium |
|||||||
| 8+ | Tegafur/Gimeracil/Oteracil Potassium | |||||||
| ≈ 19 |
Irinotecan liposome + Oxaliplatin + (5-Fluorouracil + Calcium folinate) |
|||||||
| T02002 | MELTVR | CR (-69.4%) | 1+ |
Albumin paclitaxel+ Cisplatin+Bevacizumab |
CR | Hypersensitization | 30 | Yes |
| 8+ | Bevacizumab | |||||||
SD stable disease, CR complete response, PR partial response, MELTVR myoepithelioma-like tumor of the vulvar region
* Efficacy of the injected lesion
# Lymph Node Dissection